Form 8-K - Current report:
SEC Accession No. 0001847367-25-000026
Filing Date
2025-05-14
Accepted
2025-05-14 16:11:02
Documents
15
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alms-20250514x8k.htm   iXBRL 8-K 32878
2 EX-99.1 alms-20250514xex99d1.htm EX-99.1 153859
3 GRAPHIC alms-20250514xex99d1001.jpg GRAPHIC 4353
  Complete submission text file 0001847367-25-000026.txt   330204

Data Files

Seq Description Document Type Size
4 EX-101.SCH alms-20250514.xsd EX-101.SCH 3262
5 EX-101.LAB alms-20250514_lab.xml EX-101.LAB 15918
6 EX-101.PRE alms-20250514_pre.xml EX-101.PRE 10318
17 EXTRACTED XBRL INSTANCE DOCUMENT alms-20250514x8k_htm.xml XML 4850
Mailing Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 650-231-6625
ALUMIS INC. (Filer) CIK: 0001847367 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42143 | Film No.: 25945583
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)